Allergy最新文献

{"title":"Aerosol Measurements and Decadal Changes: The Role of Climatic Changes and How It Reflects in Respiratory Allergies and Asthma","authors":"Stelios Kazadzis,&nbsp;Illias Fountoulakis,&nbsp;Athanasios Damialis,&nbsp;Akriti Masoom,&nbsp;Kyriakoula Papachristopoulou,&nbsp;Stefanie Gilles,&nbsp;Martine Collaud Coen,&nbsp;Fiona Tummon,&nbsp;Benoît Crouzy,&nbsp;Bernard Clot,&nbsp;Yagiz Pat,&nbsp;Marie-Charlotte Brüggen,&nbsp;Stephan Nyeki,&nbsp;Ioannis-Panagiotis Raptis,&nbsp;Stavros Solomos,&nbsp;Antonis Gkikas,&nbsp;Anna Moustaka,&nbsp;Natalia Kouremeti,&nbsp;Cezmi A. Akdis","doi":"10.1111/all.16602","DOIUrl":"10.1111/all.16602","url":null,"abstract":"<p>The causative agents of respiratory allergies are bioaerosols, such as house dust mite feces, pollen grains, and fungal spores. Climate change and urbanization are considered to lead to an increase in the load of allergenic bioaerosols due to impacts on plant phenophases and allergenicity. Continuous and efficient monitoring of the atmospheric composition worldwide is essential, given the major changes involved and their impact on climate change. The complexity of the exposome, evolving from single to multiple complex exposures, is explored in this work. Acquiring information from interdisciplinary scientific disciplines, such as aerobiology (for airborne particles of biological origin), aerosol science (for airborne particles of chemical or inorganic material), and integrating this with the actual reactome of patients with respiratory diseases, we aim to provide evidence of the multifactorial nature of this interaction in real life. The objective of this review is to present how we can monitor aerosols and mostly monitor the exposome, especially the biological one, i.e., pollen and fungal spores, and what their impact is, or could be, on respiratory allergies. A huge technological advancement has been required, as traditional methods of particle collection and identification have been based on tedious laboratory procedures, with delays of more than a week. This has limited their practical use to allergic patients and their treating physicians. Automation, real-time high temporal resolution, and the use of artificial intelligence are being increasingly used in medicine. Likewise, this overview summarizes the current aerosol measurement and modeling capabilities and discusses the classification of various aerosol particles and their impact on respiratory allergies. Satellite remote sensing is highlighted as a solution to the gaps in global aerosol representation by examining aerosol load in the atmospheric column in major cities worldwide. We also discuss potential novel threats, such as pioneer bioaerosols and the respiratory epithelial barrier, as well as future insights into the impact of climate change on allergy and asthma. We conclude with a discussion of emerging co-exposures and co-diseases resulting from the ongoing climate change.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 6","pages":"1613-1628"},"PeriodicalIF":12.6,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16602","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence: Cellular Rhinitis-A Key Yet Overlooked Factor in the Management of Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction (ETD).","authors":"Matteo Gelardi","doi":"10.1111/all.16609","DOIUrl":"https://doi.org/10.1111/all.16609","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"35 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144146137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria.","authors":"Marcus Maurer,Martin Metz,John Anderson,Neetu Talreja,Diane Young,Elizabeth Crowley,Margo Heath-Chiozzi,Rick Ma,Elsa Paradise,Thomas Hawthorne,Diego Alvarado,Jonathan A Bernstein","doi":"10.1111/all.16598","DOIUrl":"https://doi.org/10.1111/all.16598","url":null,"abstract":"BACKGROUNDChronic spontaneous urticaria (CSU) is characterized by mast cell (MC)-mediated wheals and/or angioedema without identifiable triggers and is driven by MC activation. Barzolvolimab-a monoclonal anti-KIT antibody-depletes MCs by inhibiting activation of KIT by stem cell factor. We evaluated multiple ascending doses in patients with CSU.METHODSPhase 1b double-blind placebo-controlled trial (NCT04538794) in adults with moderate-to-severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine-refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12-week follow-up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9). Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]). Pharmacokinetics and pharmacodynamics were assessed.RESULTSPatients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3-42.0) for barzolvolimab-treated, UAS7 = 35.8 (19.0-42.0) for placebo-treated, and 44% prior omalizumab use. Multiple doses of barzolvolimab were well tolerated. Hair color change was the commonest adverse event in barzolvolimab-treated patients. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks; 71% of patients achieved a well-controlled (UAS7 ≤ 6) response and 57% a complete response (UAS7 = 0). Additionally, 77% of barzolvolimab-treated patients achieved a well-controlled response (UCT ≥ 12) and 43% a complete response (UCT = 16) by Week 12. The kinetics of disease activity paralleled tryptase suppression, indicative of MC inhibition. Patients with and without prior omalizumab treatment responded similarly.CONCLUSIONSThis study supports barzolvolimab as a promising treatment for CSU.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"12 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations in Gut Microbiota Composition Are Related to Disease Severity and Systemic Inflammation in Patients With Chronic Urticaria.","authors":"Han-Ki Park,Young Her,Doo Young Choi,Tansol Park,Jae-Woo Kwon","doi":"10.1111/all.16601","DOIUrl":"https://doi.org/10.1111/all.16601","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"172 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 2 Immunity Promotes Neonatal Lung Progenitor Developmental Activity Through the STAT6 Signaling Axis","authors":"Chien-Chia Liao,&nbsp;Chiao-Juno Chiu,&nbsp;Bor-Luen Chiang","doi":"10.1111/all.16604","DOIUrl":"10.1111/all.16604","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 6","pages":"1807-1810"},"PeriodicalIF":12.6,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking Exosomal MicroRNA Signatures in Sputum and Peripheral Blood to Inflammatory Endotypes in Severe Asthma","authors":"D. Sanz-Rubio,&nbsp;E. Vera,&nbsp;J. Rodríguez-Sanz,&nbsp;J. Cubero,&nbsp;R. Langarita,&nbsp;M. Aguado,&nbsp;L. Pastor,&nbsp;L. Martín,&nbsp;M. Marín-Oto,&nbsp;A. R. Remacha,&nbsp;M. Ruiz,&nbsp;V. Gil,&nbsp;J. A. Domingo,&nbsp;J. A. Carretero,&nbsp;J. M. Marín","doi":"10.1111/all.16578","DOIUrl":"10.1111/all.16578","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 7","pages":"2073-2076"},"PeriodicalIF":12.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Impact of Allergic Diseases and Asthma—The HEAD Pan-European Registry","authors":"Ioana Agache,&nbsp;Maria Torres,&nbsp;Ibon Eguiluz-Gracia,&nbsp;Elena Bradatan,&nbsp;Kamal El Abd,&nbsp;Maria Beatrice Bilo,&nbsp;Federica Rivolta,&nbsp;Andrea Sangalli,&nbsp;Roxana Bumbacea,&nbsp;Selda Ali,&nbsp;Dario Antolin,&nbsp;Águeda Concepción Lario Cuenda,&nbsp;Vicente Albéndiz,&nbsp;Maria Miguel Oliveira,&nbsp;Paulo Jorge Nogueira,&nbsp;Loreto Carmona,&nbsp;HEAD Study Group","doi":"10.1111/all.16596","DOIUrl":"10.1111/all.16596","url":null,"abstract":"<p>The Health Economics of Allergic Diseases (HEAD) registry is a European-based registry developed by the European Academy of Allergy and Clinical Immunology in collaboration with national allergy societies to facilitate standardised allergic disease management. Using an observational design, this first registry-based study describes care patterns for allergic diseases and their impact on the healthcare system (diagnostic and management costs), society (missed work/school days and disability pension/support) and patients (out-of-pocket costs) in 778 adults and children with allergic rhinitis, asthma, atopic dermatitis and food allergy, from four countries (Belgium, Italy, Romania and Spain). The average total costs per patient and per year were €1329.55 ± 1947.39, with indirect costs of €338.68 ± 1629.61. Direct costs consisted of €82.74 ± 585.90 for hospitalisations, €17.50 ± 125.07 for the emergency department, €172.94 ± 323.17 for specialists, €22.70 ± 132.42 for primary care, €4.85 ± 136.84 for psychologists, €21.24 ± 82.47 for diagnosis and €104.81 ± 469.26 for treatments. Indirect costs were out-of-pocket consultation fees (€16.24 ± 106.40), medications (€161.90 ± 710.58), transportation (€44.15 ± 218.51), private insurance (€16.77 ± 157.91), avoidance (€8.65 ± 92.99) and environmental control (€99.33 ± 955.23). Adults missed 1.02 ± 3.20 workdays, children missed 0.53 ± 2.18 schooldays and burdened their families with 1.38 ± 13.83 lost days. There was a high degree of heterogeneity across countries for management patterns and for costs. The significant burden of allergic diseases calls for immediate action for better management.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 6","pages":"1677-1701"},"PeriodicalIF":12.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16596","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Legends of Allergy and Immunology: Werner Pichler.","authors":"Lukas Joerg,Arthur Helbling,Oliver Hausmann,Daniel Yerly","doi":"10.1111/all.16597","DOIUrl":"https://doi.org/10.1111/all.16597","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"132 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the Connection Between Atopic Dermatitis and Cardiovascular Diseases: Analysis of Clinical Associations and Cardiometabolic Proteins.","authors":"Danielle Fehr,Van Hung Huynh-Tran,Laura Maintz,David Niederseer,Milad Ameri,Anita Dreher,Cezmi A Akdis,Roger Lauener,Claudio Rhyner,Claudia Traidl-Hoffmann,Peter Schmid-Grendelmeier,Thomas Bieber,Marie-Charlotte Brüggen","doi":"10.1111/all.16588","DOIUrl":"https://doi.org/10.1111/all.16588","url":null,"abstract":"BACKGROUNDThere are conflicting data on a potential association between atopic dermatitis (AD) and cardiovascular diseases (CVD). The aim of this study was to further explore this connection and whether there are biomarkers indicating the risk for CVD in AD patients.METHODSWe included 677 AD patients and 79 nonatopic controls from an observational multicenter case-control study (ProRaD: Prospective longitudinal study investigating the remission phase in patients with atopic dermatitis and other allergy-associated diseases). AD severity and atopic, metabolic, and cardiovascular conditions as well as risk factors were assessed. Serum samples were analyzed with targeted proteomics (cardiometabolics panel, Olink).RESULTSWe did not find an overall association between AD and CVD. However, AD patients without atopic comorbidities (pure AD) showed a significantly higher CVD prevalence than AD patients with atopic comorbidities (ADAC) (28.2% [37/131] vs. 14.7% [80/546], p < 0.001). Yet, this association could not be confirmed when controlling for cardiovascular risk factors. In pure AD, patients with CVD showed a more severe AD than those without CVD (median EASI [Eczema Area and Severity Index] 12.9 vs. 4.0, p < 0.001). In this subgroup of patients, EASI remained a significant predictor of CVD even in the adjusted model (adjusted odds ratio [aOR] = 1.05, p = 0.040). Forty serum cardiometabolic proteins were upregulated in AD patients compared with nonatopic controls. CC-chemokine ligand 18 (CCL18) was upregulated in both AD (p < 0.001) and CVD (p < 0.001) and its increase correlated with AD severity.CONCLUSIONSOur study does not suggest an overall association between AD and CVD, but a more complex relation between the two conditions. Disease severity may be a risk factor for CVD in pure AD patients, but not in those with atopic comorbidities. CCL18 may be a biomarker for CVD.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"10 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IFNγ Signaling Impairs Regulatory B Cell Function Resulting in Worse Control of Esophageal Food Allergy.","authors":"Rachel L Clement,Julie Dilollo,Eric M Rodríguez-López,Cleandre M Guerrier,David A Hill","doi":"10.1111/all.16594","DOIUrl":"https://doi.org/10.1111/all.16594","url":null,"abstract":"BACKGROUNDEosinophilic Esophagitis (EoE) is a chronic food allergy that causes esophageal inflammation and fibrosis and manifests with symptoms of reflux, chest pain, swallowing difficulty, and food impactions. Though the prevalence of EoE is increasing by ~15% each year, our understanding of EoE immunopathology is limited. A noted feature of EoE is the presence of food-specific IgG4 antibodies in the circulation and esophageal tissue. Production of IgG4 is confined to IL-10+ B cells (Bregs) in other allergic diseases, suggesting Bregs may be present in EoE.METHODSWe examined circulating Bregs in patients with EoE milk allergy. In parallel, we performed mechanistic investigations of the role of Bregs in a murine model of food-antigen-dependent EoE. Flow cytometry and histologic analyses were used to assess esophageal and draining lymph node immune cells, and in vitro assays were used to evaluate Breg functional capacity.RESULTSBreg frequency was reduced in both EoE milk allergic subjects and an EoE disease model. Murine Breg suppressive capacity was impaired during EoE-like inflammation. Inducible deletion of Breg-derived IL-10 worsened EoE-like inflammation, while adoptive transfer of IL-10 sufficient Bregs suppressed DC activation and improved esophageal eosinophilia. IFNγ was sufficient to suppress Breg expansion and IL-10 production in vitro and contributed to Breg dysfunction and esophageal inflammation in vivo.CONCLUSIONBregs play an immunoregulatory role during EoE by controlling esophageal eosinophilia but are functionally impaired due to IFNγ-mediated signaling. These findings have important implications for understanding EoE's etiology and implementing future therapies that target IFNγ.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"41 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}